- Home
- CFFN vs TSHA Comparison
CFFN vs TSHA Comparison
Compare CFFN & TSHA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CFFN
- TSHA
- Stock Information
- Founded
- CFFN 1893
- TSHA 2019
- Country
- CFFN United States
- TSHA United States
- Employees
- CFFN N/A
- TSHA N/A
- Industry
- CFFN Savings Institutions
- TSHA Biotechnology: Pharmaceutical Preparations
- Sector
- CFFN Finance
- TSHA Health Care
- Exchange
- CFFN Nasdaq
- TSHA Nasdaq
- Market Cap
- CFFN 823.4M
- TSHA 728.4M
- IPO Year
- CFFN 1999
- TSHA 2020
- Fundamental
- Price
- CFFN $6.24
- TSHA $2.54
- Analyst Decision
- CFFN Hold
- TSHA Strong Buy
- Analyst Count
- CFFN 2
- TSHA 6
- Target Price
- CFFN $6.50
- TSHA $8.17
- AVG Volume (30 Days)
- CFFN 682.9K
- TSHA 2.6M
- Earning Date
- CFFN 07-23-2025
- TSHA 08-11-2025
- Dividend Yield
- CFFN 5.44%
- TSHA N/A
- EPS Growth
- CFFN N/A
- TSHA N/A
- EPS
- CFFN 0.12
- TSHA N/A
- Revenue
- CFFN $192,483,000.00
- TSHA $7,224,000.00
- Revenue This Year
- CFFN $9.86
- TSHA N/A
- Revenue Next Year
- CFFN $10.13
- TSHA N/A
- P/E Ratio
- CFFN $53.40
- TSHA N/A
- Revenue Growth
- CFFN N/A
- TSHA N/A
- 52 Week Low
- CFFN $4.90
- TSHA $1.05
- 52 Week High
- CFFN $7.20
- TSHA $3.31
- Technical
- Relative Strength Index (RSI)
- CFFN 52.96
- TSHA 52.72
- Support Level
- CFFN $6.15
- TSHA $2.34
- Resistance Level
- CFFN $6.46
- TSHA $2.81
- Average True Range (ATR)
- CFFN 0.13
- TSHA 0.15
- MACD
- CFFN -0.02
- TSHA 0.01
- Stochastic Oscillator
- CFFN 35.71
- TSHA 53.68
About CFFN Capitol Federal Financial Inc.
Capitol Federal Financial Inc is a bank holding company that operates through its wholly-owned subsidiary bank, Capitol Federal Savings Bank. The bank is a community-oriented financial institution that offers a variety of financial services through tens of locations. It primarily serves metropolitan areas within the state of Kansas. The bank performs traditional banking functions such as deposit-taking activities and investing that money in first-lien residential mortgages. It also participates in commercial real estate loans with other lenders, investing those funds in various securities. The vast majority of the bank's loan portfolio is in originated one- to four-family real estate loans. Its primary source of income is net interest income.
About TSHA Taysha Gene Therapies Inc.
Taysha Gene Therapies Inc is a patient-centric gene therapy company to eradicate monogenic CNS disease. It is focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the CNS in both rare and large patient populations. The company develops and commercializes transformative gene therapy treatments. Its product pipeline includes, TSHA-102 which is a is a self-complementary intrathecally delivered AAV9 gene transfer therapy in clinical evaluation for Rett syndrome.